Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

1.

Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B.

George Rosenker KM, Paquette WD, Johnston PA, Sharlow ER, Vogt A, Bakan A, Lazo JS, Wipf P.

Bioorg Med Chem. 2015 Jan 31. pii: S0968-0896(15)00067-X. doi: 10.1016/j.bmc.2015.01.043. [Epub ahead of print]

PMID:
25703307
2.

Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.

Axelrod MJ, Mendez RE, Khalil A, Leimgruber SS, Sharlow ER, Capaldo B, Conaway M, Gioeli DG, Weber MJ, Jameson MJ.

Head Neck. 2014 Jul 2. doi: 10.1002/hed.23822. [Epub ahead of print]

PMID:
24986420
3.

p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.

Axelrod MJ, Gordon V, Mendez RE, Leimgruber SS, Conaway MR, Sharlow ER, Jameson MJ, Gioeli DG, Weber MJ.

Cell Signal. 2014 Aug;26(8):1627-35. doi: 10.1016/j.cellsig.2014.03.013. Epub 2014 Mar 21.

4.

Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents.

Sharlow ER, Wipf P, McQueeney KE, Bakan A, Lazo JS.

Expert Opin Investig Drugs. 2014 May;23(5):661-73. doi: 10.1517/13543784.2014.892579. Epub 2014 Mar 13. Review.

PMID:
24625356
5.

Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity.

Sharlow ER, Leimgruber S, Murray S, Lira A, Sciotti RJ, Hickman M, Hudson T, Leed S, Caridha D, Barrios AM, Close D, Grögl M, Lazo JS.

ACS Chem Biol. 2014 Mar 21;9(3):663-72. doi: 10.1021/cb400800q. Epub 2013 Dec 23.

PMID:
24328400
6.

Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death.

Lazo JS, Sharlow ER, Epperly MW, Lira A, Leimgruber S, Skoda EM, Wipf P, Greenberger JS.

J Pharmacol Exp Ther. 2013 Dec;347(3):669-80. doi: 10.1124/jpet.113.208421. Epub 2013 Sep 25.

7.

Drug discovery algorithm for cutaneous leishmaniasis.

Grogl M, Hickman M, Ellis W, Hudson T, Lazo JS, Sharlow ER, Johnson J, Berman J, Sciotti RJ.

Am J Trop Med Hyg. 2013 Feb;88(2):216-21. doi: 10.4269/ajtmh.11-0812. Review.

8.

In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts.

Guo J, Clausen DM, Beumer JH, Parise RA, Egorin MJ, Bravo-Altamirano K, Wipf P, Sharlow ER, Wang QJ, Eiseman JL.

Cancer Chemother Pharmacol. 2013 Feb;71(2):331-44. doi: 10.1007/s00280-012-2010-z. Epub 2012 Oct 30.

9.

Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay.

Zellefrow CD, Sharlow ER, Epperly MW, Reese CE, Shun T, Lira A, Greenberger JS, Lazo JS.

Radiat Res. 2012 Sep;178(3):150-9. Epub 2012 Jul 2.

PMID:
22747550
10.

Design, Synthesis, and Biological Evaluation of PKD Inhibitors.

George KM, Frantz MC, Bravo-Altamirano K, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P.

Pharmaceutics. 2011;3(2):186-228. doi: 10.3390/pharmaceutics3020186.

11.

Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity.

Sharlow ER, Mustata Wilson G, Close D, Leimgruber S, Tandon M, Reed RB, Shun TY, Wang QJ, Wipf P, Lazo JS.

PLoS One. 2011;6(10):e25134. doi: 10.1371/journal.pone.0025134. Epub 2011 Oct 5.

12.

Identification of Inhibitors of Trypanosoma brucei Hexokinases.

Sharlow E, Golden JE, Dodson H, Morris M, Hesser M, Lyda T, Leimgruber S, Schroeder CE, Flaherty DP, Weiner WS, Simpson D, Lazo JS, Aubé J, Morris JC.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Dec 15 [updated 2011 Jun 24].

13.

Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D.

Bravo-Altamirano K, George KM, Frantz MC, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P.

ACS Med Chem Lett. 2011 Feb 14;2(2):154-159.

14.

Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review.

Shun TY, Lazo JS, Sharlow ER, Johnston PA.

J Biomol Screen. 2011 Jan;16(1):1-14. doi: 10.1177/1087057110389039. Epub 2010 Dec 15.

PMID:
21160066
15.

Protein kinase D as a potential new target for cancer therapy.

LaValle CR, George KM, Sharlow ER, Lazo JS, Wipf P, Wang QJ.

Biochim Biophys Acta. 2010 Dec;1806(2):183-92. doi: 10.1016/j.bbcan.2010.05.003. Epub 2010 May 24. Review.

16.

Chemical genetics of Plasmodium falciparum.

Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, Smithson DC, Connelly M, Clark J, Zhu F, Jiménez-Díaz MB, Martinez MS, Wilson EB, Tripathi AK, Gut J, Sharlow ER, Bathurst I, El Mazouni F, Fowble JW, Forquer I, McGinley PL, Castro S, Angulo-Barturen I, Ferrer S, Rosenthal PJ, Derisi JL, Sullivan DJ, Lazo JS, Roos DS, Riscoe MK, Phillips MA, Rathod PK, Van Voorhis WC, Avery VM, Guy RK.

Nature. 2010 May 20;465(7296):311-5. doi: 10.1038/nature09099.

17.

Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility.

Lavalle CR, Bravo-Altamirano K, Giridhar KV, Chen J, Sharlow E, Lazo JS, Wipf P, Wang QJ.

BMC Chem Biol. 2010 May 5;10:5. doi: 10.1186/1472-6769-10-5.

18.

A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity.

Sharlow ER, Lyda TA, Dodson HC, Mustata G, Morris MT, Leimgruber SS, Lee KH, Kashiwada Y, Close D, Lazo JS, Morris JC.

PLoS Negl Trop Dis. 2010 Apr 13;4(4):e659. doi: 10.1371/journal.pntd.0000659.

19.

Anti-leishmanial drug discovery: rising to the challenges of a highly neglected disease.

Sharlow ER, Grögl M, Johnson J, Lazo JS.

Mol Interv. 2010 Apr;10(2):72-5. doi: 10.1124/mi.10.2.4. Review. No abstract available.

PMID:
20368366
20.

Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen.

Sharlow ER, Close D, Shun T, Leimgruber S, Reed R, Mustata G, Wipf P, Johnson J, O'Neil M, Grögl M, Magill AJ, Lazo JS.

PLoS Negl Trop Dis. 2009 Nov 3;3(11):e540. doi: 10.1371/journal.pntd.0000540.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk